4-[4-(1-cyclohexylamino-ethyl)-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid ethyl ester | 723307-98-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-[4-(1-cyclohexylamino-ethyl)-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid ethyl ester
• 英文别名: 4-[4-(l-Cyclohexylamino-ethyl)-naphthalene-1-sulfonylamino)-piperidine-1-carboxylic acid ethyl ester；ethyl 4-[[4-[1-(cyclohexylamino)ethyl]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate
• CAS: 723307-98-0
• 化学式: C₂₆H₃₇N₃O₄S
• 分子量: 487.663
• InChiKey: DVORBERHSCDBAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  96.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-(4-acetyl-naphthalene-1-sulfonylamino)-piperidine-1-carboxylic acid ethyl ester 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 4-[4-(1-cyclohexylamino-ethyl)-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  Aryl sulfonamides useful as inhibitors of chemokine receptor activity

  摘要：

  本发明提供一般式I的化合物:或其药学上可接受的盐，其中R1、X、Z、R2、X.、Ar、n、R3和R4在本文中一般和子集中定义。本发明的化合物是CCR8的抑制剂，因此可用于治疗各种炎症和过敏性疾病。

  公开号：

  US20050085518A1

文献信息

• [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DE CCR8
  申请人：MILLENNIUM PHARM INC

  公开号：WO2004058736A1

  公开（公告）日：2004-07-15

  Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.

  揭示了一种由结构式（I）表示的CCR8抑制剂。还揭示了包括药用载体或稀释剂和由结构式（I）表示的CCR8抑制剂的药物组合物。还揭示了通过向受试者施用CCR8抑制剂来治疗炎症性疾病的方法。
• [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DU CCR8
  申请人：MILLENNIUM PHARM INC

  公开号：WO2004058709A1

  公开（公告）日：2004-07-15

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  揭示了由结构式（I）代表的CCR8抑制剂。结构式（I）中的变量在此处描述。还揭示了通过向受试者施用所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。
• CCR8 Inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040209948A1

  公开（公告）日：2004-10-21

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I): 1 The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  本发明涉及由结构式（I）表示的CCR8抑制剂：1结构式（I）中的变量在此文中进行了描述。本发明还涉及通过向受试者给予所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。
• CCR8 inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US07378525B2

  公开（公告）日：2008-05-27

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I): The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  本发明揭示了由结构式（I）表示的CCR8抑制剂：结构式（I）中的变量在此处描述。本发明还揭示了通过向受试者施用所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，尤其是哮喘的方法。
• CCR8 INHIBITORS
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：EP1590327A1

  公开（公告）日：2005-11-02